HARP News and Press, Harpoon Therapeutics Inc. From 05/16/22

Harpoon Therapeutics (NASDAQ:HARP) stock rose ~26% on May 16 after Wedbush upgraded the company's shares to Outperform from Neutral with a price target of $7, up from $5, on model tweaks related to the HPN328 program. Wedbush analyst is awaiting updated data from a phase 1/2 study o...

Gainers: Harpoon Therapeutics (HARP) +18%. Grove (GRVI) +11%. NanoViricides NNVC +11%. Travere Therapeutics TVTX +9%. Compass Therapeutics (CMPX) +4%. Losers: Chimerix CMRX -58%. Eliem Therapeutics ELYM -29%. Humacyte (HUMA) -20%. Va...

Harpoon Therapeutics press release (NASDAQ:HARP): Q1 GAAP EPS of -$0.62 misses by $0.07. Revenue of $5.91M (-34.3% Y/Y) misses by $2.17M. “We continue to advance our robust pipeline of T cell engagers and explore their therapeutic potential in areas of unmet medical need,” said&...

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. ...

Swiss pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) and clinical-stage biotech, Harpoon Therapeutics (NASDAQ:HARP) have entered into a clinical supply agreement for the delivery of Roche’s (OTCQX:RHHBY) cancer therapy atezolizumab (Tecentriq) in studies that Harpoon (HARP) expects to ...

SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to sup...

Gainers: Avadel Pharmaceuticals  (AVDL) +31%. AlloVir (ALVR) +7%. Redbox Entertainment  (RDBX) +6%. CymaBay Therapeutics  (CBAY) +5%. Harpoon Therapeutics. (HARP) +5%. Losers: Protagonist Therapeutics (PTGX) -41%. Nkarta (NKTX) -6%. Provention Bio (PRVB...

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with preclinical data for its TriTAC-XR T cell engager platform at the American Associ...

The clinical-stage immunotherapy company, Harpoon Therapeutics (NASDAQ:HARP) is trading ~4% lower in the post-market Thursday after announcing the departure of its Chief Medical Officer, Natalie Sacks, effective June 01, 2022. However, Dr. Sacks will serve the company as a consultan...

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that Natalie Sacks, M.D., Chief Medical Officer, will be leaving the company effective June 1, ...